Feeds:
Posts
Comments

Posts Tagged ‘WALL ST JOURNAL’

WALL ST JOURNAL: New wonder drug for treating advanced prostate cancer, Provenge, is finally making money for its manufacturer, Dendreon Corp. READ MORE>

Since the $93,000 treatment was launched at the beginning of May, doctors have written 500 prescriptions for the treatment, the company disclosed.

Read Full Post »

WALL ST JOURNAL: Scientists may soon be able to answer the agonising question facing men with prostate cancer: Does their cancer need immediate treatment or can it be left alone? READ MORE>

AND: Some men with low Gleason scores have cancer that spreads quickly, while some with high scores don’t. READ MORE>

Read Full Post »

WALL ST JOURNAL: The US government says it will begin analysis on whether the Dendreon company’s expensive immunotherapy treatment for prostate cancer – Provenge – is “reasonable and necessary.” READ MORE> (you need to subscribe)

The answer to that debate – the latest hurdle in Dendreon’s push to get Provenge used – will affect sales of the costly treatment.

If the Centers for Medicare and Medicaid Services covers it, that would increase the number of patients eligible and likely prompt private insurers to do the same. A denial by CMS could severely stifle the product’s growth.

Read Full Post »

WALL ST JOURNAL: Scientists may soon be able to answer the agonising question facing men with prostate cancer: does their cancer need immediate treatment or can it be left alone? READ MORE> and HERE> and HERE>

Read Full Post »

WALL ST JOURNAL: The US Food and Drug Administration has approved Jevtana, a chemotherapy drug used in combination with the steroid prednisone to treat men with advanced prostate cancer. READ MORE> and HERE>

Read Full Post »

AUGUST 5: WALL ST JOURNAL: “Decison aids” to help people decide on the best treatment for diseases like prostate cancer have been developed by the Foundation for Informed Medical Decision Making, which grew out of research at Dartmouth University in New Hampshire, US. READ MORE>

Read Full Post »

JUNE 24: WALL ST JOURNAL: Shares of Medarex Inc. (MEDX) surged Monday on news that two patients taking the biopharmaceutical company’s prostate cancer treatment in a mid-stage trial are now cancer free. READ MORE>

Read Full Post »